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Abstract The traditional shell chicken chorioallan-
toic membrane (CAM) model has been used exten-
sively in cancer research to study tumor growth and
angiogenesis. Here we present a combined in vivo
tumor spheroid and shell-less CAM three-dimensional
model for use in quantitative and qualitative analysis.
With this model, the angiogenic and tumorigenic
environments can be generated locally without exog-
enous growth factors. This physiological model offers
astable,staticandﬂatenvironmentthatfeaturesalarge
workingareaandwiderﬁeldofviewusefulforimaging
and biomedical engineering applications. The short
experimental time frame allows for rapid data acqui-
sition, screening and validation of biomedical devices.
Themethodandapplicationofthisshell-lessmodelare
discussed in detail, providing a useful tool for
biomedical engineering research.
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Introduction
Effective investigations in cancer research, whether
in tumor dynamics, drug delivery, drug or diagnostic
tool development involves the use biological models
that reﬂect physiologic characteristics of solid
tumors. Three-dimensional in vitro models and in
vivo models are increasingly used to study tumor
growth and for diagnostic and therapeutic screening
applications (Kanzawa and Saijo 1997; Rupniak et al.
1983; Zietarska et al. 2007). Three-dimensional in
vitro models include cultured biopsies, and multi-
layer cultures such as cell clusters and spheroids
(Sonoda et al. 2003). While there are currently no
high throughput in vivo models, the use of the chick
CAM has become popular as ‘moderate throughput’
screening procedure (Ribatti et al. 2001). However, a
major limitation of this in vivo model is time
constraint, and thus tumor growth is limited in size
and relative maturation.
Three-dimensional spheroids are tissue engineered
from a small cluster of individual cells that in
suspension in culture medium grow into natural
multilayered spheroid bundles (Santini and Rainaldi
1999). Unlike cell monolayers, in vivo solid tumors
grow in a three dimensional fashion, with different
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availability and environmental signals. Because oxy-
gen can diffuse efﬁciently into the tissue up to
200 lm in distance, cell regions more than 200 lm
away from oxygen and nutrient supply frequently
become necrotic, and solid tumors are often found to
contain necrotic regions due to nutrient deﬁciency
(Santini and Rainaldi 1999). Tumor spheroids mimic
the early growth and morphological dynamics of
solid tumors. When tumor spheroids grow over
approximately 200 lm in radius, nutrients cannot
diffuse readily to the center of the spheroids. This
creates a unique cellular spatial conformation across
the spheroid; the outer layer is populated with
proliferating cells due to their direct contact with
surrounding nutrients and oxygen; the center devel-
ops a necrotic core like solid tumors due to hypoxia
created by low oxygen content; and the layer between
center and the outer layer is populated by quiescent or
non-proliferating cells. Though avascular, tumor
spheroids can mature to sizes ranging from 1 to
2 mm in diameter. This is typically the size at which
an angiogenic switch would be manifested in a
successful, aggressive tumor. It is beyond this stage
that further growth of spheroids in vitro is of
diminishing value.
Here, we have exploited the fact that spheroid
tumors can develop for several weeks in an avascular
microenvironment (in vitro). Transplantation of these
preformed tumors into the CAM model extends the
utility of the CAM, permitting the study of later
stages in tumor development than otherwise possible.
The symmetric 3D conﬁguration of tumor spheroids
facilitates the generation of boundary conditions and
ﬁxed data points useful in quantitative investigations,
such as computational modeling of tumor growth
(Chaplain 1996; Liang et al. 2005). Moreover, the
ability to use spheroids rather than biopsy fragments
for this purpose allows for genetic manipulation of
the tumors cells not easily accomplished with tumor
biopsies.
The traditional CAM model, ﬁrst introduced as the
shell model (Knighton et al. 1977), remains useful for
various tumor biology studies. However, it is not
optimal for imaging and biomedical engineering
investigations due to restricted access to tumor sites
and the relative unstable environment of shell (both
due to fragility and the ability of the embryo to move
freely in the presence of perturbations). Drug
injections and imaging studies can be challenging.
Here, we describe the combined use of spheroids in
the shell-less assay (Jakobson et al. 1989; Ono 2000),
which has the advantages of stability, ease of access,
large area and amenability to serial quantitative
analysis (Online Resource 1). The model provided is
robust and versatile, allowing adaptation for studies
of tumor pathology and therapeutic efﬁcacy.
Materials and methods
3-D spheroid preparation
To create in vitro cultures of spheroids, we use a
variation of the liquid-overlay technique (Santini and
Rainaldi 1999). Single cell suspensions (0.5 9
10
6 tumor cells/ml) are added to non-treated agar
coated (2%) square Petri dishes (BD Falcon square
Petri dish) 100 9 15 mm ﬁlled with culture medium,
and incubated at 37 C and 7.5% CO2. After 3 days of
incubation, tumor cell aggregates are transferred to
non-agar coated (regular) Petri dishes ﬁlled with cell
culture medium, and grown to tumor spheroids of
approximately 500 lm to 1.0 mm in diameter (Online
Resource 2).
Shell-less CAM preparation
Shell-less CAM preparation is conducted on day 3 of
embryonic development (EA). Fertilized white (Leg-
horn, lab grade) or brown (Rhode Island, lab grade)
chicken eggs (AA Lab Eggs, Inc, Westminster, CA),
disinfected with 70% alcohol or germicidal cloths
(Sani-Cloth Plus, PDI: The Healthcare Division of
Nice-Pak Products, Inc., Orangeburg, NY), are incu-
bated in a static ventilated hatching incubator set at
38 C and 60% humidity.
Under clean and light restricted conditions, the
contents of the egg are carefully dropped by force of
gravity in a dry and sterile condiment dish 4.5 cm
diameter (bottom), 6.5 cm diameter (top), 4.5 cm
height. Dishes are available from several viable
suppliers including Wal-Mart.
The dish is subsequently covered with a breathable
polyethylene sheet (Fisher brand all-purpose labora-
tory wrap polyvinyl-chloride, Fisher Scientiﬁc, Pitts-
burgh, PA), and incubated. Additional holes can be
added using an 18G needle to ensure gas exchange.
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spheroid implantation. The detailed protocol of the
technique can be found under the supplemental
materials (Online Resource 3).
Tumor spheroid implantation
Tumor spheroid implantation is conducted on day 7
or 8 of embryonic development. Under sterile con-
ditions, a small incision is made using a 30 gauge
hypodermic needle attached to a 1 cc syringe, in the
upper surface (ectodermal epithelium) of the CAM in
a region away from major blood vessels. A small area
of the chorionic layer of the CAM is scratched with
the edge of the needle’s bevel. The ectodermal
epithelium has been successfully removed when the
target area appears watery due to local ischemia. Any
resulting sera, blood or debris is gently aspirated with
the syringe. Finally, one tumor spheroid of 500 lm
3
to 1.0 mm
3 in size is dropped onto the severed area
using a spatula (Online Resource 4). The dish is then
covered with a semi-porous sheet, and returned to the
incubator.
Successful implantation is observed when the
tumor spheroid is engulfed by the CAM (typically
2 days post-implantation), and the tumor spheroid
rests in the highly vascularized mesodermal layer
between the allantoic epithelium (endoderm) and the
healed chorionic epithelium (ectoderm). At this stage,
the model is ready for use in biological and biomed-
ical engineering investigations.
Discussion
Vascularized tumor spheroids from a variety of
human derived tumor cell lines have been generated
using this method including MCF-7 breast cancer,
BXPC-3 pancreatic cancer, NB5 neuroblastoma,
U-87 and ACBT (ACBT-G., Granger, University of
California, Irvine) glioblastoma cell lines.
Microvasculature in the center region of the
surface of the spheroid during day 14 of embryonic
stage is evident in Fig. 1a. Five distinct microvessels
were found at the center of the spheroid (Fig. 1b)
upon examination of the middle histological section
of the H&E stained CAM/tumor spheroid tissue.
Invasion of the tumor cells to adjacent areas of the
CAM is also observed.
Figure 1a shows successful development of the
tumor vascular network using this CAM/tumor model
withouttheuseofexogenousgrowthfactors.Although
there is presence of angiogenic activity on the CAM
due to embryogenesis and wound healing of the
chorionic epithelium, penetration of the blood vessels
tothecenterofthetumorisevidencethatvesselgrowth
into the tumor is induced by angiogenic factors
endogenous to the tumor. High angiogenic activity
was observed in spheroids of 500 lm–1 mm in
diameter as opposed to 2 mm spheroids (not shown).
It is possible that spheroids larger than 1 mm diameter
are inefﬁciently embedded in the CAM. Therefore, the
top portion of the spheroid would not be nourished by
the mesoderm ﬂuid and would dry out. Spheroids
smallerthan500 lmaremorechallengingtospotwith
thenakedeyeduetotheirsizeandtransparencyasthey
are less compact than larger spheroids. Thus, they can
be difﬁcult to locate on the CAM post implantation.
Spheroids between 500 lm and 1 mm tend to yield
optimal results.
Figure 1 shows the presence of new tumors,
evidence of breakdown and clearance of the necrotic
Fig. 1 a Top view of tumor spheroid and CAM interface—a
1 mm diameter ACBT glioblastoma spheroid inside CAM
(mesoderm) on live chicken embryo on day 14 EA; b H&E
histological section of 1 mm diameter glioblastoma spheroid
embedded in CAM. Grey area is the CAM; center region in
purple denotes the tumor spheroid. Other purple regions
denote tumor cells. Tumor microvasculature as a result of
angiogenesis (1–5), and new tumor invaded regions are
observed
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123core, and invasion of the tumor cells in surrounding
areas of the CAM. These results suggest that this
CAM/tumor model can also be used to study tumor
invasion and metastasis in addition to tumor growth
and angiogenesis.
The efﬁcacy of drugs can also be tested using this
CAM/tumor model (Vargas et al. 2007). In thera-
peutic and imaging studies, depending on the goal of
the investigation, drugs are often administered to the
system topically, intraperitoneally or intravenously.
Nanoparticles carrying therapeutic drugs can be
introduced into the CAM vascular system via the
intraperitoneal and intravenous delivery techniques.
With our spheroid based shell-less CAM model, drug
and therapeutic efﬁcacy as well as the potential of
nanoparticle target selectivity and delivery for cancer
treatment can be assessed. In the topical delivery
method, the drug is administered directly onto the
target site without invasive perturbation the CAM.
Alternatively, slow release gels (depot effect) con-
taining a drug of choice can be applied on the CAM/
spheroid interface. While the topical technique pro-
vides fast and direct delivery of the drug to the target
site, it does not mimic drug applications for cancer
treatment in a clinical setting. Intraperitoneal and
intravenous delivery methods are invasive techniques
that most closely match the clinical setting. Unlike
the topical application where the actual concentration
of the drug delivered reaches the target, the intra-
peritoneal application results in slower delivery as the
drug is ﬁrst absorbed by the host and subsequently the
dosage may be lower when it reaches the target
tumor. In addition, intraperitoneal delivery can result
in lower survival rate because critical organs of the
embryo may be compromised. Intravenous delivery
provides rapid drug delivery into the closed vascular
network of the CAM.
A drawback of the shell-less CAM model is that
survival rate of the embryo is somewhat lower than of
the shell CAM due in part to the absence of calcium
supply during the embryo development (Dunn et al.
1987). To overcome this drawback, the number of
embryos used during the experiments should be
adjusted to match the data requirements of the
individual research. In addition, the relatively short
experimental window (approximately 10 days after
implantation) over which experiments can be con-
ducted due to the ﬁxed embryonic stage of the chicken
embryo, limits the model to short term studies. The
shell-less tumor spheroid based CAM model should
therefore be used as a transitional model to obtain
rapid validation of biomedical engineering applica-
tions, and studies of long term effects of the applica-
tions should be conducted in alternate in vivo models
feasible for these types of studies.
By combining two classical systems, the tumor
spheroid and the shell-less CAM, we have developed
an in vivo model that is not only easily adaptable and
applicable to many scientiﬁc ﬁelds, but one which
can provide fast and efﬁcient means to quantitatively
investigate cancer pathology, test developing non-
invasive medical imaging technologies, and evaluate
new therapies.
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